natgillin/translations-raw huggingface dataset:
På grundlag af kendte metaboliske profiler forventes der ikke klinisk signifikante interaktioner mellem Lopinavir/Ritonavir Mylan og dapson, trimethoprim/sulfamethoxazol, azithromycin eller fluconazol.
Based on known metabolic profiles, clinically significant interactions are not expected between Lopinavir/Ritonavir Mylan and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Der blev taget en række blodprøver før dosering og med intervaller i løbet af 12 timer i 2. og 3. trimester, ved fødslen, og 4-6 uger efter fødslen (hos kvinder som fortsatte behandlingen efter fødslen) til farmakokinetisk analyse af koncentrationen af total og ubundet lopinavir i plasma.
A series of blood samples were collected pre-dose and at intervals over the course of 12 hours in trimester 2 and trimester 3, at birth, and 4-6 weeks postpartum (in women who continued treatment postdelivery) for pharmacokinetic analysis of total and unbound levels of plasma lopinavir concentrations.
Enogtres patienter gennemførte studiet (35 patienter fik den anbefalede dosis på 400/100 mg to gange dagligt under hele studieforløbet).
Sixty-one patients completed the study (35 patients received the recommended 400/100 mg twice daily dose throughout the study).
Hydroxypropylcellulose
Hydroxypropylcellulose Talc
Følgende tabel indeholder doseringsvejledning for lopinavir/ritonavir-tabletter baseret på BSA, når de anvendes til børn i kombination med efavirenz eller nevirapin.
The following table contains dosing guidelines for lopinavir/ritonavir tablets based on BSA when used in combination with efavirenz or nevirapine in children.
Tinnitus, vertigo
Uncommon Tinnitus, vertigo
De gennemsnitlige ændringer i PR-interval fra baseline strækker sig fra 11,6 ms til 24,4 ms i et interval på 12 timer efter dosen.
The mean changes from baseline in PR interval ranged from 11.6 ms to 24.4 ms in the
Et længerevarende virologisk respons over for lopinavir/ritonavir (i kombination med nukleosid/nukleotid revers transkriptasehæmmere) er ligeledes observeret i et mindre fase II-studie (M97-720) efter 360 ugers behandling.
Sustained virological response to lopinavir/ritonavir (in combination with nucleoside/nucleotide reverse transcriptase inhibitors) has been also observed in a small Phase II study (M97-720) through 360 weeks of treatment.
Pædiatrisk doseringsvejledning uden samtidig efavirenz eller nevirapin* Vægt (kg)
Paediatric dosing guidelines without concomitant efavirenz or nevirapine* Weight (kg)
Patienterne fik emtricitabin 200 mg en gang dagligt og tenofovir DF 300 mg en gang dagligt.
Patients were administered emtricitabine 200 mg once daily and tenofovir DF 300 mg once daily.
Indledning af digoxin-behandling til patienter, som allerede tager Lopinavir/Ritonavir Mylan, vil sandsynligvis resultere i lavere stigninger digoxin-koncentrationer end forventet.
Initiation of digoxin in patients already taking Lopinavir/Ritonavir Mylan is likely to result in lower than expected increases of digoxin concentrations.
Lopinavir/ritonavir tabletter har også udvist mindre farmakokinetisk variation i forbindelse med et måltid sammenlignet med lopinavir/ritonavir bløde kapsler.
Lopinavir/ritonavir tablets have also shown less pharmacokinetic variability under all meal conditions compared to lopinavir/ritonavir soft capsules.
I denne gruppe var følgende mutationer i hiv-protease forbundet med nedsat følsomhed overfor lopinavir in vitro: L10F/I/R/V, K20M/R, L24I, M46I/L, F53L, I54L/T/V, L63P, A71I/L/T/V,
Within this panel, the following mutations in HIV protease were associated with reduced in vitro susceptibility to lopinavir: L10F/I/R/V, K20M/R, L24I, M46I/L, F53L, I54L/T/V, L63P, A71I/L/T/V, V82A/F/T, I84V and L90M.
Gennemsnitsalderen for de deltagende patienter var 39 år (interval: 19 til 71); 75 % var kaukasere og 78 % var mænd.
Mean age of patients enrolled was 39 years (range: 19 to 71); 75% were Caucasian, and 78% were male.
Symptomer på svimmelhed, uklarhed, besvimelse eller fornemmelse af unormal hjerterytme.
− Symptoms of dizziness, lightheadedness, fainting or sensation of abnormal heartbeats.
Samtidig administration med andre hiv-proteasehæmmere (PIs) I henhold til gældende behandlingsvejledninger anbefales samtidig behandling med to proteasehæmmere generelt ikke.
Co-administration with other HIV protease inhibitors (PIs) According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended.
Dosis til voksne af lopinavir/ritonavir-tabletter (400/100 mg to gange daglig) kan anvendes til børn på 40 kg eller derover eller med en legemsoverflade (BSA)* større end 1,4 m2. Til børn som vejer mindre end 40 kg eller med en legemsoverflade (BSA) på mellem 0,5 og 1,4 m2, og som er i stand til at synke tabletter, henvises der til nedenstående skema med doseringsretningslinjer.
The adult dose of lopinavir/ritonavir tablets (400/100 mg twice daily) may be used in children 40 kg or greater or with a Body Surface Area (BSA)* greater than 1.4 m2. For children weighing less than 40 kg or with a BSA between 0.5 and 1.4 m2 and able to swallow tablets, please refer to the dosing guideline tables below.
Langtids karcinogenicitetsstudier af lopinavir/ritonavir i mus viste en ikke genotoksisk, mitogen induktion af levertumorer, som generelt menes at have lille relevans for mennesker.
Long-term carcinogenicity studies of lopinavir/ritonavir in mice revealed a nongenotoxic, mitogenic induction of liver tumours, generally considered to have little relevance to human risk.
I gruppen med en daglig administration viste ingen af patienterne lopinavir-resistens, og i gruppen med to daglige administrationer viste 1 patient, som havde signifikant proteasehæmmer-resistens ved baseline, yderligere lopinavir-resistens i studiet.
In the QD group, no patient demonstrated lopinavir resistance, and in the BID group, 1 patient who had significant protease inhibitor resistance at baseline demonstrated additional lopinavir resistance on study.
Børnene kunne inkluderes, når de var < 18 år, vejede ≥ 15 kg, fik cART, der omfattede lopinavir/ritonavir, havde hiv-1-ribonukleinsyre (RNA) < 50 kopier/ml i mindst 24 uger og var i stand til at synke tabletter.
Children were eligible when they were aged <18 years, ≥15 kg in weight, receiving cART that included lopinavir/ritonavir, HIV-1 ribonucleic acid (RNA) <50 copies/ml for at least 24 weeks and able to swallow tablets.
Højere tenofovir-koncentrationer kan forstærke tenofovirassocierede bivirkninger, herunder nyrelidelser.
Higher tenofovir concentrations could potentiate tenofovir associated adverse events, including renal disorders.
Gennemsnitsalderen for de deltagende patienter var 41 år (interval: 21 til 73); 51 % var kaukasere og 66 % var mænd.
Mean age of patients enrolled was 41 years (range: 21 to 73); 51% were Caucasian and 66% were male.
Den gennemsnitlige steady-state dalkoncentration forud for morgendosen var 5,5 ± 5,4 µg/ml.
The mean steady-state trough concentration prior to the morning dose was 5.5 ± 5.4 μg/ml.
Kvalme, opkastning og mavesmerter, da en stor stigning i mængden af triglycerider (fedtstoffer i blodet) anses for at være en risikofaktor for pankreatitis (betændelse i bugspytkirtlen), og disse symptomer kan tyde på denne sygdom.
− Nausea, vomiting, abdominal pain as large increases in the amount of triglycerides (fats in the blood) have been considered a risk factor for pancreatitis (inflammation of the pancreas) and these symptoms may suggest this condition.
I in vitro studier blev klonede humane kardiale kalium kanaler (HERG) inhiberet 30 % af de højeste testede koncentrationer af lopinavir/ritonavir, svarende til en lopinavir eksponering på 7 gange det totale og 15 gange det frie peak plasma niveau, som opnås i mennesker ved de maksimalt anbefalede doser.
During in vitro studies, cloned human cardiac potassium channels (HERG) were inhibited by 30% at the highest concentrations of lopinavir/ritonavir tested, corresponding to a lopinavir exposure 7-fold total and 15-fold free peak plasma levels achieved in humans at the maximum recommended therapeutic dose.
lopinavir/ritonavir kan forårsage ændringer i din hjerterytme og i den elektriske aktivitet i hjertet.
Lopinavir/ritonavir may cause changes in your heart rhythm and the electrical activity of your heart.
Lopinavir/ritonavir må ikke tages sammen med lægemidler, hvis clearance er stærkt afhængige af CYP3A og for hvilke forhøjede plasmakoncentrationer er forbundet med alvorlige og/eller livstruende tilfælde.
Lopinavir/ritonavir should not be co-administered with medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life threatening events.
Plasmakoncentrationen af lopinavir blev målt over fire 12-timers perioder i løbet af det andet trimester (gestationsuge 20-24), tredje trimester inden dosisøgning (gestationsuge 30), tredje trimester efter dosisøgning (gestationsuge 32) og 8 uger efter fødslen.
Plasma concentrations of lopinavir were measured over four 12-hour periods during second trimester (20-24 weeks gestation), third trimester before dose increase (30 weeks gestation), third trimester after dose increase (32 weeks gestation), and at 8 weeks post-partum.
Lopinavir/ritonavir ordineres til brug i kombination med andre antivirale lægemidler.
- Lopinavir/ritonavir is prescribed for use in combination with other antiviral medicines.
Patienterne bør monitoreres tæt for nedsat VPA-effekt, når Lopinavir/Ritonavir Mylan og valproinsyre eller valproat gives samtidig.
Patients should be monitored closely for a decreased VPA effect when Lopinavir/Ritonavir Mylan and valproic acid or valproate are given concomitantly.
Ved steady state resulterede de to regimer i ekspositioner på dag 3, som var tilnærmelsesvis 1,5 og 3-gange højere end dem, som blev set med den anbefalede LPV/r dosis en gang daglig eller to gange daglig.
The two regimens resulted in exposures on Day 3 which were approximately 1.5 and 3-fold higher than those observed with recommended oncedaily or twicedaily LPV/r doses at steady state.
I gruppen med en daglig administration viste 6/75 (8 %) patienter nye primære proteasehæmmermutationer (codon 30, 32, 48, 50, 82, 84, 90), ligesom 12/77 (16 %) patienter i gruppen med to daglige administrationer.
In the QD group, 6/75 (8%) patients demonstrated new primary protease inhibitor mutations (codons 30, 32, 48, 50, 82, 84, 90), as did 12/77 (16%) patients in the BID group.
Embryoføtotoksisitet (spontan abort, nedsat føtal levedygtighed, nedsat føtal kropsvægt, øget frekvens af skeletforandringer) og postnatal udviklingstoksicitet (nedsat overlevelse af afkom) var observeret i rotter ved maternelt toksiske doser.
In rats, embryofoetotoxicity (pregnancy loss, decreased foetal viability, decreased foetal body weights, increased frequency of skeletal variations) and postnatal developmental toxicity (decreased survival of pups) was observed at maternally toxic dosages.
Hvis den samtidige administration vurderes at være uundgåelig, kan en øget dosis af Lopinavir/Ritonavir Mylan på 400 mg/400 mg to gange daglig administreres med rifampicin under nøje sikkerheds-og terapeutisklægemiddelovervågning.
If this coadministration is judged unavoidable, increased dose of Lopinavir/Ritonavir Mylan at 400 mg/400 mg twice daily may be administered with rifampicin under close safety and therapeutic drug monitoring.
Patienter, der har disse tegn eller symptomer, bør vurderes, og lopinavir/ritonavirbehandling bør seponeres, hvis diagnosen pankreatitis stilles (se pkt.
Patients who exhibit these signs or symptoms should be evaluated and lopinavir/ritonavir therapy should be suspended if a diagnosis of pancreatitis is made (see section 4.8).
Hvis du tager sildenafil eller tadalafil og lopinavir/ritonavir sammen, kan du risikere at få bivirkninger såsom lavt blodtryk, besvimelse, synsændringer og rejsning af penis, der varer mere end 4 timer.
− If you take sildenafil or tadalafil and lopinavir/ritonavir together, you may be at risk of side effects such as low blood pressure, passing out, visual changes and penile erection lasting more than 4 hours.
Hiv-1 blev inkuberet in vitro med lopinavir alene og med lopinavir plus ritonavir i koncentrationer, der svarer til de forskellige plasmakoncentrationer, der ses under behandling med lopinavir/ritonavir.
HIV-1 has been passaged in vitro with lopinavir alone and with lopinavir plus ritonavir at concentration ratios representing the range of plasma concentration ratios observed during lopinavir/ritonavir therapy.
Alfa1-antagonist Alfuzosin
Alpha1 adrenoreceptor antagonist Alfuzosin
Det er vist, at ritonavir inducerer metaboliske enzymer, som forårsager induktion af dens egen metabolisme, og sandsynligvis induktion af lopinavir metabolisme.
Ritonavir has been shown to induce metabolic enzymes, resulting in the induction of its own metabolism, and likely the induction of lopinavir metabolism.
Resultater ved uge 48: Studie M98-863 Lopinavir/ritonavir (N = 326)
Outcomes at Week 48: Study M98-863 Lopinavir/ritonavir (N=326)
Lopinavir/ritonavirs virkning (i kombination med andre antiretrovirale stoffer) på biologiske markører (plasma-hiv-RNA-niveauer og CD4+ T-celletælling) er blevet vurderet i kontrollerede studier med lopinavir/ritonavir af 48 uger til 360 ugers varighed.
The effects of lopinavir/ritonavir (in combination with other antiretroviral agents) on biological markers (plasma HIV RNA levels and CD4+ T-cell counts) have been investigated in controlled studies of lopinavir/ritonavir of 48 to 360 weeks duration.
Abnorme drømme, nedsat libido
Anxiety Uncommon Abnormal dreams, libido decreased
Særlig forsigtighed skal udvises ved ordinering af lopinavir/ritonavir og lægemidler med kendt forlængende virkning på QT-intervaller såsom: chlorpheniramin, quinidin, erthromycin, clarithromycin.
Particular caution must be used when prescribing lopinavir/ritonavir and medicinal products known to induce QT interval prolongation such as: chlorpheniramine, quinidine, erythromycin, clarithromycin.
Middeltallet for EC50 for lopinavir mod isolater med 0- 3, 4-5, 6-7 og 8-10 mutationer i de aminosyre codons, der er beskrevet ovenfor, var henholdsvis 0,8, 2,7, 13,5 og 44,0 gange højere end EC50 mod vildtype hiv.
The median EC50 of lopinavir against isolates with 0 − 3, 4 − 5, 6 − 7 and 8 − 10 mutations at the above amino acid positions was 0.8, 2.7, 13.5 and 44.0-fold higher than the EC50 against wild type HIV, respectively.
Lopinavir/ritonavir bør ordineres af en læge, der har erfaring med behandling af hiv-infektioner.
Lopinavir/ritonavir should be prescribed by physicians who are experienced in the treatment of HIV infection.
I tilfælde af plastbeholdere skal indholdet anvendes inden for 120 dage efter anbrud.
For plastic containers, use within 120 days after first opening.
* Tabletterne må ikke tygges, deles eller knuses.
* The tablets must not be chewed, broken or crushed.
Gennem 360 ugers behandling blev der udført en succesfuld genotype-analyse af virale isolater hos 19 ud af 28 patienter med bekræftet hiv-RNA over 400 kopier/ml og ingen primære eller aktiv sitemutationer i protease (aminosyrer i positionerne 8, 30, 32, 46, 47, 48, 50, 82, 84 og 90) eller proteasehæmmer-fænotyperesistens blev vist.
Through 360 weeks of treatment, genotypic analysis of viral isolates was successfully conducted in 19 of 28 patients with confirmed HIV RNA above 400 copies/ml revealed no primary or active site mutations in protease (amino acids at positions 8, 30, 32, 46, 47, 48, 50, 82, 84 and 90) or protease inhibitor phenotypic resistance.
Titandioxid (E171)
Hypromellose Titanium dioxide (E171) Macrogol
Lopinavirs effektive halveringstid (fra maksimum til minimum) over et doseringsinterval på 12 timer er i gennemsnit 5-6 timer, og lopinavirs tilsyneladende orale clearance (CL/F) er 6 til 7 l/t.
The effective (peak to trough) half-life of lopinavir over a 12 hour dosing interval averaged 5 - 6 hours, and the apparent oral clearance (CL/F) of lopinavir is 6 to 7 l /h.
Ammende kvinder må ikke tage lopinavir/ritonavir uden lægens specifikke anvisning.
− Breast-feeding mothers should not take lopinavir/ritonavir unless specifically directed by the doctor.
Hvis en bivirkning forhindrer dig i at tage lopinavir/ritonavir som anvist, skal du straks informere din læge om det.
− If a side effect is preventing you from taking lopinavir/ritonavir as directed tell your doctor right away.
Baseret på de data, der er tilgængelige på nuværende tidspunkt, bør lopinavir/ritonavir ikke administreres en gang daglig til pædiatriske patienter (se pkt.
Based on the current data available, lopinavir/ritonavir should not be administered once daily in paediatric patients (see section 5.1).
HDPE-flaske med hvidt, uigennemsigtigt polypropylenskruelåg med aluminiumsinduktionsforsegling og tørremiddel.
HDPE bottle with white opaque polypropylene screw cap with aluminium induction sealing liner wad and desiccant.
Patienter uden forudgående antiretroviral behandling
Patients without prior antiretroviral therapy
Lopinavir/ritonavir forårsager sandsynligvis en stigning i plasmakoncentrationen af lægemidler, der fortrinsvis metaboliseres af CYP3A.
Lopinavir/ritonavir is likely to increase plasma concentrations of medicinal products that are primarily metabolised by CYP3A.
Potente CYP3A4-hæmmere, som f.eks. proteasehæmmere, kan øge bedaquilin-eksponeringen, hvilket potentielt kan øge risikoen for bedaquilin-relaterede bivirkninger.
Strong CYP3A4 inhibitors such as protease inhibitors may increase bedaquiline exposure which could potentially increase the risk of bedaquiline related adverse reactions.
I tillæg til mutationerne beskrevet ovenfor er mutation V32I og I47A blevet observeret i rebound-isolater med nedsat lopinavir-følsomhed hos proteasehæmmer-erfarne-patienter, som fik lopinavir/ritonavir-behandling, og mutation I47A og L76V blevet observeret i rebound-isolater med nedsat lopinavir-følsomhed hos proteasehæmmer-erfarnepatienter, som fik lopinavir/ritonavir-behandling
In addition to the mutations described above, mutations V32I and I47A have been observed in rebound isolates with reduced lopinavir susceptibility from protease inhibitor experienced patients receiving lopinavir/ritonavir therapy, and mutations I47A and L76V have been observed in rebound isolates with reduced lopinavir susceptibility from patients receiving lopinavir/ritonavir therapy.
Ved administration sammen med Lopinavir/Ritonavir Mylan er den anbefalede rifabutin-dosis 150 mg 3 gange om ugen på fastsatte dage (for eksempel mandag-onsdagfredag).
When given with Lopinavir/Ritonavir Mylan the recommended dose of rifabutin is 150 mg 3 times per week on set days (for example MondayWednesday-Friday).
Efter en dosis 400/100 mg 14C-lopinavir/ritonavir kan cirka 10,4  2,3 % og 82,6  2,5 % af den indgivne dosis genfindes henholdsvis i urin og fæces.
After a 400/100 mg 14C-lopinavir/ritonavir dose, approximately 10.4 ± 2.3% and 82.6 ± 2.5% of an administered dose of 14C-lopinavir can be accounted for in urine and faeces, respectively.
HDPE-flaske: Skal anvendes inden for 120 dage efter anbrud.
HDPE bottle: After first opening, use within 120 days.
Til spædbørn og små børn, der ikke er i stand til at synke hele tabletter, skal det undersøges, om der findes bedre egnede formuleringer af lopinavir/ritonavir.
For infants and young children unable to swallow tablets, more suitable formulations containing lopinavir/ritonavir should be checked for their availability.
Den gennemsnitlige sammenlægning af IC50 for lopinavir for disse 18 isolater ved baseline og rebound var henholdsvis 6.9- og 63-gange sammenlignet med vildtype-virus.
The median fold IC50 of lopinavir for these 18 isolates at baseline and rebound was 6.9- and 63-fold, respectively, compared to wild type virus.
Den inducerede QRS-interval-forlængelse fra 6 ms til 9,5 ms med høj-dosis lopinavir/ritonavir (henholdsvis 800/200 mg to gange daglig) medvirker til QT-forlængelse.
The induced QRS interval prolongation from 6 ms to 9.5 ms with high dose lopinavir/ritonavir (800/200 mg twice daily) contributes to QT prolongation.
Lopinavirs antivirale effekt mod laboratorie og kliniske hiv-stammer in vitro er undersøgt i henholdsvis akut inficerede lymfoblast cellelinjer og perifere blodlymfocytter.
The in vitro antiviral activity of lopinavir against laboratory and clinical HIV strains was evaluated in acutely infected lymphoblastic cell lines and peripheral blood lymphocytes, respectively.
(kombination af mekanismer inklusive hæmning af CYP3A)
(combinations of mechanisms including CYP3A inhibition)
Den anbefalede standarddosis af lopinavir/ritonavir -tabletter er 400/100 mg (to 200/50 mg tabletter) to gange dagligt med eller uden mad.
The standard recommended dosage of lopinavir/ritonavir tablets is 400/100 mg (two 200/50 mg) tablets twice daily taken with or without food.
Der er rapporteret post-marketing tilfælde, som indikerer en mulig interaktion mellem levothyroxin og produkter, der indeholder ritonavir.
Post-marketing cases have been reported indicating a potential interaction between ritonavir containing products and levothyroxine.
En mere udtalt virkning på DM-6705 eksponering kan ses ved langvarig samtidig administration med lopinavir/ritonavir.
A more pronounced effect on DM-6705 exposure may be observed during prolonged co-administration with lopinavir/ritonavir.
Andre bivirkninger, der er blevet rapporteret med lopinavir/ritonavir: gulfarvning af huden eller det hvide i øjnene (gulsot), alvorlige eller livstruende hududslæt og blister (Stevens-Johnsons syndrom og erythema multiforme).
Other side effects that have been reported with lopinavir/ritonavir: yellowing of the skin or whites of eyes (jaundice), severe or life threatening skin rashes and blisters (Stevens-Johnson syndrome and erythema multiforme).
Studiet havde ingen kontrolgruppe af patienter, der ikke fik lopinavir/ritonavir.
The study did not contain a control arm of patients not receiving lopinavir/ritonavir.
Lopinavir gennemsnitlig steady-state AUC, Cmax og Cmin var henholdsvis 72,6  31,1 g•h/ml, 8,2  2,9 g/ml og 3,4  2,1 g/ml efter lopinavir/ritonavir oral opløsning 230/57,5 mg/m2 to gange dagligt uden nevirapin (n = 12) og var henholdsvis 85,8  36,9 g•h/ml, 10,0  3,3 g/ml og 3,6  3,5 g/ml efter 300/75 mg/m2 to gange dagligt med nevirapin (n = 12).
The lopinavir mean steady-state AUC, Cmax, and Cmin were 72.6 ± 31.1 μg•h/ml, 8.2 ± 2.9 μg/ml and 3.4 ± 2.1 μg/ml, respectively after lopinavir/ritonavir oral solution 230/57.5 mg/m2 twice daily without nevirapine (n=12), and were 85.8 ± 36.9 μg•h/ml, 10.0 ± 3.3 μg/ml and 3.6 ± 3.5 μg/ml, respectively after 300/75 mg/m2 twice daily with nevirapine (n=12).
Stivhed i led, ømhed og smerter (især i hofte, knæ og skulder) og indskrænket bevægelighed, da nogle patienter, som tager disse lægemidler, kan udvikle en knoglesygdom, der kaldes knoglenekrose (hvor knoglevævet dør som følge af nedsat blodtilførsel til knoglen).
− Joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty in movement as some patients taking these medicines may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone).
Der bør udvises særlig forsigtighed ved ordination af Lopinavir/Ritonavir Mylan til patienter, som tager digoxin, da den akutte hæmmende effekt af ritonavir på Pgp forventes at få digoxin-niveauet til at stige betydeligt.
Particular caution should be used when prescribing Lopinavir/Ritonavir Mylan in patients taking digoxin as the acute inhibitory effect of ritonavir on Pgp is expected to significantly increase digoxin levels.
Efter 48 ugers behandling med lopinavir/ritonavir, efavirenz og nukleosid revers transkriptasehæmmere, blev plasma hiv-RNA  400 kopier/ml observeret hos 93 % (25/27), 73% (11/15), og 25 % (2/8) of af patienterne med følsomhed ved baseline, der var henholdsvis < 10 gange, 10-40 gange, og > 40 gange nedsat overfor lopinavir.
After 48 weeks of treatment with lopinavir/ritonavir, efavirenz and nucleoside reverse transcriptase inhibitors, plasma HIV RNA ≤ 400 copies/ml was observed in 93% (25/27), 73% (11/15), and 25% (2/8) of patients with < 10-fold, 10 to 40-fold, and > 40-fold reduced susceptibility to lopinavir at baseline, respectively.